Cargando…
Metformin reduces 12-month change in body weight among people newly commenced on clozapine: a retrospective naturalistic cohort study
BACKGROUND: People with schizophrenia have a 15–20-year reduction in life expectancy, driven in part by the metabolic effects of antipsychotics. Clozapine is associated with the highest rates of weight gain. As clozapine remains the most effective antipsychotic for treatment-resistant schizophrenia...
Autores principales: | Spokes, Jessica, Hollingworth, Samantha, Winckel, Karl, Kisely, Steve, Baker, Andrea, Cosgrove, Peter, Siskind, Dan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970229/ https://www.ncbi.nlm.nih.gov/pubmed/33796266 http://dx.doi.org/10.1177/20451253211000609 |
Ejemplares similares
-
CoMET: a randomised controlled trial of co-commencement of metformin versus placebo as an adjunctive treatment to attenuate weight gain in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2021) -
CoMET: a protocol for a randomised controlled trial of co-commencement of METformin as an adjunctive treatment to attenuate weight gain and metabolic syndrome in patients with schizophrenia newly commenced on clozapine
por: Siskind, Dan, et al.
Publicado: (2018) -
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
por: Mayfield, Karla, et al.
Publicado: (2015) -
T160. TREATMENT OF CLOZAPINE-ASSOCIATED OBESITY AND DIABETES WITH EXENATIDE (CODEX) IN ADULTS WITH SCHIZOPHRENIA: A RANDOMISED CONTROLLED TRIAL
por: Siskind, Dan, et al.
Publicado: (2018) -
Metformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
por: Siskind, Dan J., et al.
Publicado: (2016)